Analyst Ratings Published 10/07/2025, 09:30 pm 0 Goldman Sachs resumes Immunovant stock coverage with Neutral rating IMVT -1.75% ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage of Halozyme Therapeutics (NASDAQ: HALO) with a Neutral rating and a $55.00 price target. The company, which has achieved a perfect ...

Analyst Ratings Published 10-07-2025, 06:02 pm 0 Morgan Stanley resumes Capital One stock coverage with Overweight rating COF -0.54% ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage on CG Oncology (NASDAQ: CGON) with a Buy rating and a price target of $40.00 on Thursday. The stock, currently trading at $27.04, appears ...

Investing.com - Morgan Stanley (NYSE:MS) has resumed coverage of Capital One Financial (NYSE:COF) with an Overweight rating and a price target of $261.00. According to InvestingPro data, Capital One ...

Investing.com - Goldman Sachs (NYSE: GS) resumed coverage of Immunovant (NASDAQ: IMVT) with a Neutral rating and set an $18.00 price target, close to InvestingPro ’s Fair Value calculation. The ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy rating and a price target of $97.00. The stock, currently trading at $89, has shown ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage of Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $19.00, according to a research note released Thursday. The ...

Analyst Ratings Published 07/10/2025, 03:12 AM 0 Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential AMLX 0.00% ...

Woori Bank will resume sales of non-face-to-face credit loan products that were suspended at the end of last month. On the 4th, according to the financial sector, Woori Bank informed customers ...

Analyst Ratings Published 07/02/2025, 01:57 AM 0 Citi resumes WiseTech Global stock coverage with Buy rating on Cargowise potential WTC 0.82% ...